SequelSEC

Structure Therapeutics Inc. GPCR

Pharmaceutical Preparations · CIK 0001888886 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$118.63M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Structure Therapeutics Inc. (GPCR) reported net income of -$106.16M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Structure Therapeutics Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Structure Therapeutics Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$118.63MUnavailable$23.99M-$73.79MUnavailableUnavailable-$47.06M-$45.84MUnavailableUnavailable
Net income-$106.16MUnavailable$33.00M-$65.71MUnavailableUnavailable-$36.48M-$33.98MUnavailableUnavailable
Research & development$100.06MUnavailable$68.69M$58.99MUnavailableUnavailable$33.49M$32.60MUnavailableUnavailable
Weighted-average diluted sharesshares 217.96MUnavailableUnavailableshares 175.47MUnavailableUnavailableUnavailableshares 171.63MUnavailableUnavailable
Pretax income-$105.92MUnavailable$33.17M-$65.60MUnavailableUnavailable-$36.34M-$33.88MUnavailableUnavailable
Income tax expense$234.00KUnavailable$170.00K$108.00KUnavailableUnavailable$136.00K$92.00KUnavailableUnavailable
Diluted EPS$-0.49UnavailableUnavailable$-0.37UnavailableUnavailableUnavailable$-0.20UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$18.57MUnavailable$17.57M$14.80MUnavailableUnavailable$13.57M$13.24MUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Structure Therapeutics Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$272.64MUnavailable$799.62M$102.91MUnavailableUnavailable$169.51M$172.13MUnavailableUnavailable
Total assets$1.43BUnavailable$1.58B$832.16MUnavailableUnavailable$903.33M$933.22MUnavailableUnavailable
Current assets$1.37BUnavailable$1.57B$814.02MUnavailableUnavailable$891.21M$923.65MUnavailableUnavailable
Total liabilities$71.01MUnavailable$67.54M$62.14MUnavailableUnavailable$38.49M$36.42MUnavailableUnavailable
Current liabilities$66.11MUnavailable$63.28M$57.53MUnavailableUnavailable$36.02M$33.43MUnavailableUnavailable
Total equity incl. NCI$1.35BUnavailable$1.52B$770.02MUnavailableUnavailable$864.84M$896.80MUnavailableUnavailable
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$11.13MUnavailable$13.86M$17.80MUnavailableUnavailable$8.02M$8.45MUnavailableUnavailable

Cash flow

Structure Therapeutics Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$120.12MUnavailable-$64.42M-$51.00MUnavailableUnavailable-$36.47M-$19.70MUnavailableUnavailable
Capital expenditures-$42.00KUnavailable$1.50M$1.57MUnavailableUnavailable$16.00K$685.00KUnavailableUnavailable
Investing cash flow$74.50MUnavailable$56.14M-$49.32MUnavailableUnavailable$33.23M-$189.04MUnavailableUnavailable
Financing cash flow$2.08MUnavailable$704.99M$56.20MUnavailableUnavailable$615.00K-$757.00KUnavailableUnavailable
Net change in cash-$43.53MUnavailable$696.71M-$44.11MUnavailableUnavailable-$2.62M-$209.50MUnavailableUnavailable
Stock-based compensation$12.63MUnavailable$8.07M$7.50MUnavailableUnavailable$5.83M$6.02MUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Structure Therapeutics Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailable-$65.91M-$52.57MUnavailableUnavailable-$36.48M-$20.38MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio20.75xUnavailable24.81x14.15xUnavailableUnavailable24.74x27.63xUnavailableUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailable0.5%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open GPCR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

14 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2026-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2026-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.